3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Leukemia
1
Interventions
blinatumomab
5
pegaspargase
2
Methotrexate
2
Dexamethasone
2
Daunorubicin
2
Cytarabine
2
revumenib
1
prednylidene
1
nilotinib
1
merphos
1
fludarabine
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
deltacortene
1
azathiopurine
1
auricularum
1
asparaginase erwinia chrysanthemi recombinant
1
X-Rays
1
Vincristine
1
Stem Cell Transplantation
1
Spinal Puncture
1
Specimen Handling
1
Rituximab
1
Prednisone
1
Phantoms, Imaging
1
N,N-dicyclohexyl-isoborneol-10-sulfonamide
1
Mitoxantrone
1
Midazolam
1
Mercaptopurine
1
Leucovorin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Precursor Cell Lymphoblastic Leukemia-Lymphoma
×
Cobicistat
×
Clear all
NCT04065399
2026-03-18
AUGMENT-101
Syndax Pharmaceuticals
Phase 1/2
Recruiting
447 enrolled
2 FDA